Novo Nordisk sues Teva over generic drug development

Novo Nordisk has landed in legal dispute with Israeli pharmaceutical company Teva, as the latter company is intending to launch a generic version of Novo Nordisk’s obesity treatment Saxenda.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire translated by daniel pedersen

According to a filing on the US court database, Novo Nordisk is bringing legal action against Israeli pharmaceutical company Teva, as reported by Danish business daily Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading